<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858856</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2016_SJDBT</org_study_id>
    <nct_id>NCT02858856</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients</brief_title>
  <official_title>Sipjeondaebo-tang for Alleviating Fatigue Measured by Brief Fatigue Inventory and EORTC-QLQ-C30, BR23 Score Change Among Patients With Breast Carcinoma Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catholic Kwandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study that investigate efficacy and safety of Sipjeondaebo-tang on fatigue of
      patients with breast carcinoma receiving chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Fatigue Inventory change</measure>
    <time_frame>0-5 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Fatigue Inventory change</measure>
    <time_frame>6-11 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-C30 change</measure>
    <time_frame>0-5 week, 6-11 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ-BR23 change</measure>
    <time_frame>0-5 week, 6-11 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take Sipjeondaebo-tang on 0~2 week, 3~5 week of clinical trial period, total of 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take Sipjeondaebo-tang on 6~8 week, 9~11 week of clinical trial period, total of 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sipjeondaebo-tang</intervention_name>
    <description>Herbal medicine which is a compound of 10 herbs.</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
    <other_name>Deciten granule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women aged over 18 years

          -  patients who have histologically or cytologically confirmed breast tumor

          -  patients who applicable AC(doxorubicin + cyclophosphamide)

          -  ECOG score 0 to 2

        Exclusion Criteria:

          -  patient impossible to orally intake

          -  patient with dementia, delirium and depression

          -  patient suffering from diseases like chronic hepatitis B, C or hepatocirrhosis

          -  severe liver disability (3-fold the normal high range value for ALT, AST)

          -  patient who has diabetes not controlled by diet, hypertension, hyperthyroidism,

          -  severe systemic disease

          -  use of other investigational products within the past 30 days

          -  hypersensitivity to investigational product

          -  others who are judged not to be appropriate to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunhoo Cheon</last_name>
    <phone>8229619278</phone>
    <email>khuksg@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>International St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHUNHOO CHEON, M.D.(DKM)</last_name>
      <phone>82-2-961-9278</phone>
      <email>hreedom35@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Seong-Gyu Ko</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Juzentaihoto</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

